Regenxbio (RGNX) Amortization of Deferred Charges (2021 - 2025)

Regenxbio's Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $5.1 million for Q4 2025.

• On a quarterly basis, Amortization of Deferred Charges fell 10.25% year-over-year to $5.1 million in Q4 2025; TTM through Dec 2025 was $12.9 million, a 111.46% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, up 111.46% from the prior year.
• Amortization of Deferred Charges eased to $5.1 million in Q4 2025 per RGNX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $5.7 million in Q4 2024 and bottomed at -$715000.0 in Q2 2024.
• The 5-year median for Amortization of Deferred Charges is $302500.0 (2021), against an average of $1.2 million.
• Across the five-year window, Amortization of Deferred Charges tumbled 1162.96% in 2023 and jumped 3570.32% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $125000.0 in 2021, then tumbled by 604.0% to -$630000.0 in 2022, then jumped by 124.6% to $155000.0 in 2023, then soared by 3570.32% to $5.7 million in 2024, then declined by 10.25% to $5.1 million in 2025.
• Per Business Quant, the three latest RGNX Amortization of Deferred Charges figures stand at $5.1 million (Q4 2025), $5.3 million (Q3 2025), and $2.8 million (Q2 2025).